Paradigm Biopharmaceuticals Ltd.

As of June 30, 2026, Paradigm Biopharmaceuticals Ltd. carries a market capitalization of 61.99M, placing it among publicly traded companies globally. Its enterprise value stands at 57.19M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Paradigm Biopharmaceuticals Ltd.'s next confirmed earnings release is scheduled for February 24, 2027.

As of June 30, 2026, Paradigm Biopharmaceuticals Ltd. has 584.84M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 807.89, and the price-to-book ratio stands at 29.49.

These figures are as of June 30, 2026. The EV/Sales ratio of 1,177.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 57.19M versus a market cap of 61.99M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Paradigm Biopharmaceuticals Ltd. maintains a current ratio of 1.10, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 216.37, indicating elevated leverage, while an interest coverage ratio of -24.83 demonstrates limited ability to service its debt obligations.

These figures are as of the close on September 18, 2026.

Over the twelve months ended June 30, 2026, Paradigm Biopharmaceuticals Ltd. generated 48,550.38 in revenue and converted that into -34.12M in net income, yielding earnings per share of -0.09. EBITDA reached -37.02M, while operating income came in at -37.11M.

As of June 30, 2026, Paradigm Biopharmaceuticals Ltd. holds 9.36M in cash and equivalents against 4.55M in total debt, resulting in a net debt position of -5.07M. Total book value stands at 2.10M, with working capital of 1.55M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Paradigm Biopharmaceuticals Ltd. posted a gross margin of 84.87, reflecting its pricing power and cost economics. The operating margin of -76,434.10 and net profit margin of -70,282.28 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -42.69, meaning Paradigm Biopharmaceuticals Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Paradigm Biopharmaceuticals Ltd.'s most recent stock split took place on November 1, 2023.

As of June 30, 2026, Paradigm Biopharmaceuticals Ltd. has an Altman Z-Score of -18.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.